SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA inspects Hikal’s pharmaceutical manufacturing facility at Panoli

15 May 2023 Evaluate

The U.S. Food and Drug Administration (USFDA) has inspected Hikal’s pharmaceutical manufacturing facility located at Panoli, Gujarat. The five-day detailed preapproval inspection of an API during the period May 8, 2023-May 12, 2023 was concluded with 'Zero 483 observations’ from the USFDA Agency. This latest audit re-emphasizes the company’s commitment towards maintaining the best in class quality, compliance and regulatory standards across its manufacturing sites.

Hikal is a leading manufacturer and supplier of API's and intermediates globally.


Hikal Share Price

192.15 3.60 (1.91%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×